Why Argonaut Leads in GMP Compliant Storage and Logistics for Biotech and Pharma In today’s competitive biotech and pharmaceutical landscape, efficient supply chain management isn’t just a necessity—it’s a strategic
Meet Scott Goldstein – Vice President of Strategic Partnerships, Drug Product Manufacturing at Argonaut Can you describe your role at Argonaut? No two days are ever quite the same! I
Argonaut Manufacturing Services Selected to Manufacture siRNA Medicines for Potential Prion Disease Trial Argonaut to support manufacturing needs of an siRNA therapeutic for a potential clinical trial for prion disease
Scott Goldstein, the Vice President of Strategic Partnerships at Argonaut Manufacturing Services, caught up with Perry Rearick at Outsourced Pharma to present a webinar covering Argonaut’s sterile fill-finish capabilities, recent
Optimization to Improve In Vitro Diagnostic Device Performance – Quality Control in Lyophilization Previously we discussed how diagnostic devices can be improved with optimization of lyophilization, and efficiency improvement.
Meet Richard Hargis – Sr. Director, Drug Product Manufacturing at Argonaut What’s a day in the life of a Drug Product Manufacturing Director at Argonaut? “As the Sr. Director in
4 Tips on choosing the right CMO for your biopharmaceutical For today’s biopharmaceutical manufacturers, time is of the essence. From overcoming evolving supply chain obstacles and securing materials, to ensuring
Meet Stacy Sutton – SVP/General Manager, Life Science Division at Argonaut What’s a day in the life of a General Manager at Argonaut? “As General Manager of the Life Science
In the evolving landscape of biopharmaceutical manufacturing, optimizing fill and finish plays a critical role in ensuring product quality, regulatory compliance, and operational efficiency. C-level executives looking to streamline their processes must consider innovative
Choosing a Contract Manufacturing Partner as a Smart Strategy Reshoring Pharmaceutical and Life Science manufacturing to the U.S. over the next four years presents a significant opportunity for companies